Exelon and Physical disability - a phase IV clinical study of FDA data
Summary:
Physical disability is reported as a side effect among people who take Exelon (rivastigmine tartrate), especially for people who are male, 60+ old, also take Lipitor, and have Diabetes.
The phase IV clinical study analyzes which people have Physical disability when taking Exelon. It is created by eHealthMe based on reports of 10,864 people who have side effects when taking Exelon from the FDA, and is updated regularly.
What is Exelon?
Exelon has active ingredients of rivastigmine tartrate. It is often used in alzheimer's disease. eHealthMe is studying from 11,060 Exelon users. Check the latest studies of Exelon.
What is Physical disability?
Physical disability is found to be associated with 670 drugs and 416 conditions by eHealthMe. Check the latest studies of Physical disability.
10,864 people reported to have side effects when taking Exelon.
Among them, 15 people (0.14%) have Physical disability.

Among these 15 people:
What is the gender of people who have Physical disability when taking Exelon? *
- female: 6.67 %
- male: 93.33 %
What is the age of people who have Physical disability when taking Exelon? *
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 100 %
What are other drugs people take besides Exelon? *
- Zometa: 15 people, 100.00%
- Megace: 15 people, 100.00%
- Allopurinol: 15 people, 100.00%
- Aspirin: 15 people, 100.00%
- Catapres: 15 people, 100.00%
- Celebrex: 15 people, 100.00%
- Ibuprofen: 15 people, 100.00%
- Lamisil: 15 people, 100.00%
- Zestril: 15 people, 100.00%
- Lipitor: 15 people, 100.00%
What are other side effects people have besides Physical disability? *
- Tooth Loss: 15 people, 100.00%
- Pneumonia: 15 people, 100.00%
- Injury: 15 people, 100.00%
- Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 15 people, 100.00%
- Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 15 people, 100.00%
- Ocular Icterus (presence of jaundice seen in the sclera of the eye): 15 people, 100.00%
- Stress And Anxiety: 15 people, 100.00%
- Haemorrhage (bleeding): 15 people, 100.00%
- Osteoarthritis (a joint disease caused by cartilage loss in a joint): 15 people, 100.00%
- Osteonecrosis Of Jaw (death of bone of jaw): 15 people, 100.00%
What are the existing conditions these people have? *
- Diabetes: 1 person, 6.67%
* Approximation only. Some reports may have incomplete information.
Do you take Exelon and have Physical disability?
- Check whether Physical disability is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Exelon:
- Exelon (11,060 reports)
Physical disability treatments and more:
- Physical disability (6,381 reports)
How severe was Physical disability and when was it recovered:
Expand to all the drugs that have ingredients of rivastigmine tartrate:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Exelon:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Physical disability:
- Physical disability (670 drugs)
Browse all the conditions that are associated with Physical disability:
- Physical disability (416 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on rivastigmine tartrate (the active ingredients of Exelon) and Exelon (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Temaz vs. Olanzapine, side effect and effectiveness comparison - 9 seconds ago
- Could Duexis cause Stress And Anxiety? - 10 seconds ago
- Drug interactions of Multivitamin and Combipatch - 24 seconds ago
- Could Brilinta cause Chills? - 25 seconds ago
- High Blood Cholesterol and Hypotension - 25 seconds ago
- Could Brilinta cause Sedation Aggravated? - 26 seconds ago
- Could Losartan cause Kidney Stones? - 29 seconds ago
- Could Triamcinolone Acetonide cause Conjunctivitis? - 32 seconds ago
- Could Losartan cause Eye Discharge? - 34 seconds ago
- Drug interactions of Trilipix and Keppra - 47 seconds ago